Dyne Therapeutics (NASDAQ:DYN) Rating Lowered to Strong Sell at Wall Street Zen

Posted by Stanley Muller on Aug 3rd, 2026

Dyne Therapeutics (NASDAQ:DYN – Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued to investors on Saturday.

Several other analysts have also recently weighed in on DYN. Cantor Fitzgerald began coverage on shares of Dyne Therapeutics in a report on Thursday, July 23rd. They issued an “overweight” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Friday, July 17th. TD Cowen started coverage on shares of Dyne Therapeutics in a research report on Friday, June 26th. They issued a “buy” rating for the company. Sanford C. Bernstein lifted their target price on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Finally, Morgan Stanley cut their target price on shares of Dyne Therapeutics from $47.00 to $45.00 and set an “overweight” rating on the stock in a research note on Friday. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Dyne Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $34.42.

Get Our Latest Report on DYN

Dyne Therapeutics Stock Performance

NASDAQ DYN opened at $25.18 on Friday. The stock has a market cap of $4.70 billion, a P/E ratio of -7.56 and a beta of 1.07. Dyne Therapeutics has a fifty-two week low of $9.57 and a fifty-two week high of $26.26. The stock has a 50 day simple moving average of $21.24 and a two-hundred day simple moving average of $18.88. The company has a debt-to-equity ratio of 0.28, a quick ratio of 12.02 and a current ratio of 12.02.

Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last posted its earnings results on Thursday, July 30th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.33). On average, analysts forecast that Dyne Therapeutics will post -3.28 earnings per share for the current year.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, Director Jason P. Rhodes sold 297,211 shares of the firm’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $23.26, for a total transaction of $6,913,127.86. Following the completion of the transaction, the director owned 2,962 shares of the company’s stock, valued at approximately $68,896.12. This trade represents a 99.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Erick Lucera sold 2,362 shares of the firm’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $20.37, for a total value of $48,113.94. Following the transaction, the chief financial officer directly owned 121,563 shares of the company’s stock, valued at $2,476,238.31. This represents a 1.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have bought 9,000 shares of company stock worth $156,800 and have sold 1,653,638 shares worth $36,107,304. 9.46% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. T. Rowe Price Investment Management Inc. boosted its stake in Dyne Therapeutics by 523.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock worth $343,085,000 after acquiring an additional 14,727,667 shares in the last quarter. Orbis Allan Gray Ltd bought a new position in shares of Dyne Therapeutics during the fourth quarter valued at approximately $93,926,000. Adage Capital Partners GP L.L.C. bought a new position in shares of Dyne Therapeutics during the second quarter valued at approximately $30,378,000. Perceptive Advisors LLC lifted its holdings in shares of Dyne Therapeutics by 543.7% during the fourth quarter. Perceptive Advisors LLC now owns 3,478,944 shares of the company’s stock valued at $68,048,000 after purchasing an additional 2,938,500 shares during the last quarter. Finally, Marshall Wace LLP lifted its holdings in shares of Dyne Therapeutics by 572.9% during the third quarter. Marshall Wace LLP now owns 3,013,377 shares of the company’s stock valued at $38,119,000 after purchasing an additional 2,565,570 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors.

About Dyne Therapeutics

(Get Free Report)

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.